Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 31, 2026
Systematic echocardiography in patients with hematological malignancies and Gram-positive bacteremia, is it really needed?Claudia Biosca, Mercè Aren-Jubany, Maria Dolores Quesada, et al.
Annals of Hematology|February 3, 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
Annals of Hematology|February 24, 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
Annals of Hematology|April 29, 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patientsMaría P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
European Journal of Haematology|April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocolsMarta Sitges, Blanca Boluda, Ana Garrido, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
Leukemia & Lymphoma|May 10, 2019
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registryOlga Salamero, David Martínez-Cuadrón, Marta Sobas, et al.
Blood Advances|September 1, 2021
Engraftment characterization of risk-stratified AML in NSGS miceRafael Díaz de la Guardia, Talía Velasco-Hernandez, Francisco Gutiérrez-Agüera, et al.
Pageof 9